Stock listing

Stuttgart:8AK Alkermes plc Aktie

German listing (Stuttgart) of Alkermes plc · home listing NASDAQ:ALKS

Follow Alkermes plc into a list and get an email when it puts out news.

Home listing price · NASDAQ:ALKS

$41.22 USD +1.12 (+2.8%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ALKS

Alkermes plc logo
Ticker
Stuttgart:8AK
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Calls

Replays

  • Alkermes (NASDAQ:ALKS) Q2 2026 Earnings Call

    Tue, Jul 28, 2026 · 8:00 AM ET

    Watch Transcript

  • Alkermes (NASDAQ:ALKS) Q1 2026 Earnings Call

    Tue, May 05, 2026 · 8:00 AM ET

    Watch Transcript

  • Alkermes (NASDAQ:ALKS) Q4 2026 Earnings Call

    Wed, Feb 25, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

Oct 13, 2026

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Sep 21, 2026

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

Sep 16, 2026

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Sep 10, 2026

The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Aug 24, 2026

Alkermes plc Reports Second Quarter 2026 Financial Results

Jul 28, 2026

Alkermes to Report Second Quarter Financial Results on July 28, 2026

Jul 14, 2026

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Jul 13, 2026

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

Jun 17, 2026

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

Jun 15, 2026

All Alkermes plc news

Decks

Alkermes plc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
39 in the last 12 months · 246 in all · newest Oct 13, 2026 · oldest 2019
Calls
23 calls with a replay · 23 with a transcript · latest Jul 28, 2026
Decks
70 decks · latest Jul 28, 2026

Where Alkermes plc is listed

ListingExchangeCountryCurrency
NASDAQ:ALKS · Home listingNASDAQUnited StatesUSD
LS Exchange:A1JKVHLS ExchangeGermanyEUR
Lang & Schwarz:A1JKVHLang & SchwarzGermanyEUR
BOATS:ALKSBOATSUnited StatesUSD
Frankfurt:8AKFrankfurtGermanyEUR
Tradegate:8AKTradegateGermanyEUR
Munich:8AKMunichGermanyEUR
Stuttgart:8AK · This pageStuttgartGermanyEUR
Xetra:8AKXetraGermanyEUR

Log in to ask 6ix AI your own questions about Alkermes plc.